Immediate Introduction to Medical Practice
Non-Reimbursed Prescription Available for Up to Three Years

Hai, a digital healthcare specialist company, announced on February 3 that its digital therapeutic device (DTx) for generalized anxiety disorder (GAD), "Anzeilax," has been designated by the Ministry of Health and Welfare as eligible for deferred new medical technology evaluation.


Hai's GAD DTx "Anzeilax" Confirmed for Deferred New Medical Technology Evaluation View original image

With this decision, Anzeilax can be immediately introduced into medical practice and prescribed as a non-reimbursed treatment without undergoing a separate new medical technology evaluation process.


The deferred new medical technology evaluation system allows the prioritized use of innovative medical technologies with confirmed safety for a certain period, on the condition that clinical evidence is accumulated during that time. Through this deferral, Hai will be able to utilize Anzeilax in real-world clinical settings for the next two to three years and collect real-world data (RWD).


Anzeilax is a digital therapeutic device optimized for digital environments, based on Acceptance & Commitment Therapy (ACT), which is used to treat generalized anxiety disorder. Rather than suppressing or eliminating anxiety, it provides a self-dialogue-based training program that helps patients restore their daily lives while living with anxiety. All related content was developed in-house to fit the structure of clinical interventions.


Its clinical efficacy has also been confirmed. In a confirmatory clinical trial conducted at Gangnam Severance Hospital, the group of patients who used Anzeilax in combination with medication showed an improvement in anxiety symptoms that was more than three times greater than the control group who received medication alone. After 10 weeks, the GAD-7 score improved by about 11% in the control group, compared to a 29% improvement in the Anzeilax combination group, and this effect was maintained through the 15-week follow-up. The study results were published in JMIR (Journal of Medical Internet Research), a leading academic journal in the digital health field.


According to the National Health Insurance Service, the number of anxiety disorder patients in Korea increased by 20.3%, from 745,198 in 2020 to 896,256 in 2024, and the demand for mental health treatment is rapidly expanding.


Hai plans to use this confirmation of deferred new medical technology evaluation as an opportunity to accelerate supply, focusing on major university hospitals and psychiatric clinics in Korea.



Jinwoo Kim, CEO of Hai, stated, "This decision marks a turning point where digital therapeutics move beyond the research stage to become an actual treatment option," adding, "Based on the data accumulated in clinical settings, we will simultaneously pursue listing on the national health insurance and entry into the global market."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing